Clinical Trial Search

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b) — 0; 2; 0; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX) — 75; 110; 1500 mg/m^2

Primary: Participants With a Response — 12; 19 Participants

Primary: Global Change in Brain Glucose Uptake — 30.3; 30.4 μmol/100 g/min

Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants

Primary: Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32. — 0 Number of Events

Primary: Creatinine Clearance (CrCl) in the Immediate Post-transplant Period — 5.11; 7.44; 6.30; 9.66 mL/min — p=0.9076

Primary: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough — 97.5; 97.8; 97.7; 97.8 mmHg — p=<0.001

Primary: Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test…

Primary: Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) — 40.9; 10.7 pg/mL — p=0.6281

Primary: Number of Participants With Adverse Events — 8; 7; 6; 5 Participants

Primary: 3-month Progression Free Survival Rate — 3 Participants

Primary: Number of Patients With Adverse Events — 35 Participants

Primary: Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C) — -38.8; -19.2; 0.9 Percent change — p=<0.001

Primary: CO2 Reserve (Delta-PETCO2-AT) — -3.6; -2.5; -1.8 mmHg — p=0.019